Can preoperative 25-hydroxyvitamin D levels predict transient hypocalcemia after total thyroidectomy?

Alberto Maria Saibene1 · Cecilia Rosso1 · Giovanni Felisati1 · Carlotta Pipolo1 · Simone De Leo2 · Paolo Lozza1 · Mario Gennaro Cozzolino3 · Loredana De Pasquale4

Received: 17 May 2021 / Accepted: 24 August 2021 / Published online: 26 September 2021
© The Author(s) 2021

Abstract
Transient postoperative hypocalcemia is a common complication after total thyroidectomy. Evidence on contributing metabolic factors is contradictory. Our work aims to define the role of preoperative 25-hydroxyvitaminD levels in developing transient postoperative hypocalcemia. 183 consecutive patients who underwent total thyroidectomy at our institution (May 2017–December 2019) were included in the retrospective study. We reported gender, age, estimated glomerular filtration rate, creatinine, preoperative 25-hydroxyvitaminD, serum pre- and postoperative calcium, pre- and postoperative PTH levels and transient postoperative hypocalcemia occurrences. We compared variables both among patients with and without transient postoperative hypocalcemia and between patients with different 25-hydroxyvitaminD levels (< 10 ng/ml deficitary; 11–30 ng/ml insufficient; > 30 ng/ml normal). A binomial logistic regression model evaluating the risk for transient postoperative hypocalcemia was elaborated. Patients with transient postoperative hypocalcemia had lower levels of postoperative PTH (p < 0.001) and more frequently normal or deficitary 25-hydroxyvitaminD levels (p = 0.05). When comparing patients according to their 25-hydroxyvitaminD levels, insufficiency was associated with a lower rate of transient postoperative hypocalcemia (p = 0.05); deficiency was associated with higher preoperative PTH (p = 0.021), postoperative PTH (p = 0.043) and estimated glomerular filtration rate (p = 0.031) and lower serum creatinine (p = 0.014). In the regression model higher preoperative PTH (OR = 1.011, p = 0.041) and 25-hydroxyvitaminD deficiency (OR = 0.343, p = 0.011) significantly predicted transient postoperative hypocalcemia. Data analysis revealed a correlation between transient postoperative hypocalcemia and 25-hydroxyvitaminD levels: our work points towards the possibility to stratify the risk of transient postoperative hypocalcemia according to patients’ preoperative 25-hydroxyvitaminD status.

Keywords Post-operative hypocalcemia · Post-operative hypoparathyroidism · Vitamin D · Parathyroid hormone · Total thyroidectomy complications

Introduction
Postoperative hypocalcemia and hypoparathyroidism represent one of the most common complications of total thyroidectomy (TT) [1]. Hypocalcemia affects 30–50% of patients undergoing TT. Such a high rate led some authors to define

Alberto Maria Saibene and Cecilia Rosso provided the same contribution for this work.

Mario Gennaro Cozzolino and Loredana De Pasquale provided the same contribution for this work.

* Cecilia Rosso
rosso.cecilia1@gmail.com

1 Department of Otolaryngology, Department of Health Sciences, Otolaryngology Unit ASST Santi Paolo E Carlo Università Degli Studi Di Milano, via di Rudini 8, 20154 Milan, Italy

2 Endocrinometabolic Department, Istituto Auxologico Italiano, Milan, Italy

3 Department of Health Sciences, Nephrology Unit (Head: Professor Mario G. Cozzolino), ASST Santi Paolo E Carlo, Università Degli Studi Di Milano, Milan, Italy

4 Thyroid and Parathyroid Surgery Service - Otolaryngology Unit (Head: Professor Giovanni Felisati), Department of Health Sciences, ASST Santi Paolo E Carlo, Università Degli Studi Di Milano, Milan, Italy
post-thyroidectomy hypocalcemia a sequela, rather than a complication [2, 3]. Transient postoperative hypocalcemia (TPH) usually leads to longer hospitalization and/or recovery time, additional biochemical tests, potential symptomatic deficiencies and complications, with a direct increase of healthcare costs and disease burden [1].

Various factors may facilitate TPH, among them: hypothermia, prolonged surgical time, Graves’ Disease, female sex [1]. Parathyroid glands injury or accidental removal during TT is another established critical risk factor for TPH [4, 5]. Since these factors cannot explain each clinical scenario, other factors have been alternatively analyzed to assess their relationship with TPH. Already published studies correlate TPH with low early postoperative PTH levels and with calcium deficiency [6, 7]. The American Thyroid Association indicates low postoperative PTH as a predictor of post-total thyroidectomy hypocalcemia [8].

The association between TPH and preoperative 25-hydroxyvitamin D (25(OH)D) levels, albeit widely studied, is less univocal. Some studies show an increased risk of postoperative hypocalcemia and a prolonged length of stay after TT in case of low preoperative 25(OH)D levels. Conversely, others state that 25(OH)D levels are not predictive of postoperative decrease in serum calcium [9–12]. Preliminary data indicate that calcium and 25(OH)D supplementation before TT may improve overall quality of life, shorten the hospital stay, and promote early discharge [13]. The role of pre-operative PTH levels in TPH is equally debated [14–16]. Most surprisingly, the role of serum creatinine and estimated glomerular filtration rate (eGFR) as indicator of chronic kidney disease have not been extensively studied in relationship with TPH. This despite the known mechanism that links chronic kidney disease, reduced renal activation of 25(OH)D into 1,25(OH)2D, reduced calcium absorption, and secondary PTH increase, a cycle which may indeed harbor an important role in TPH.

In this complex context, our work aims at evaluating the correlation between pre-operative factors and TPH risk in a retrospective cohort of patients undergoing TT at a single institution. More specifically, the authors aim at establishing a more definite connection between 25(OH)D levels and TPH, which may lead to future interventional strategies to decrease the incidence of this complication.

**Methods**

**Study design**

This study was conceived as a retrospective cohort study on all consecutive patients who underwent total thyroidectomy at a single institution (Santi Paolo e Carlo Hospital, Milan, Italy) from May 2017 to December 2019.

Given the retrospective nature of the study, it was granted an exemption from Internal Review Board approval, though it was conducted in full accordance with the Helsinki declaration. All patients included gave their informed consent to the surgical and medical procedures described in the study.

**Inclusion criteria:**

- Patients undergoing TT at our institution for any clinical indication

**Exclusion criteria:**

- Patients who received preoperative supplementation therapy of Calcium and/or 25(OH)D
- Patients underwent total thyroidectomy with associated central neck dissection
- Patients affected with primary hyperparathyroidism
- Patients with accidental parathyroidectomy confirmed in the final surgical pathology report
- Patients with ongoing nephropathy
- Patients with definitive postoperative hypocalcemia

**Data collection**

Medical records from 181 patients were considered eligible for the study.

For each patient we recorded information concerning sex, age at surgery, preoperative PTH levels, thyroid stimulating hormone (TSH) levels, serum calcium levels, serum creatinine levels, estimated glomerular filtration rate (eGFR), 25(OH)D levels, postoperative PTH and transient hypocalcemia during the hospital stay.

PTH was expressed as pg/ml (normal range 8.7–79.6 pg/ml). TSH was expressed as microIU/ml (normal range 0.47–4.68 microIU/ml). Serum calcium was expressed as mg/dL (normal range 8.4–10.2 mg/dL). Reported total calcium values were corrected for serum albumin levels. Serum creatinine was expressed as mg/dL (normal range 0.66–1.25 mg/dL). eGFR was calculated with the MDRD formula as described in Levy et al.[17]. 25-OH D was expressed in ng/ml. 25(OH)D levels lower than 10 ng/ml defined vitamin deficiency; 25(OH)D levels between 11 and 30 ng/ml defined vitamin insufficiency; 25(OH)D levels above 30 ng/ml were considered normal[18]. TPH was defined as serum calcium lower than 8.4 mg/dl on postoperative day one and two, recovering without need of calcium supplementation by 6 months.

**Statistical analysis and data availability**

Comparison of binomial outcomes between groups was assessed with Pearson Chi Square. Mann–Whitney test and Kruskal–Wallis test were used for comparing variables
between two and three groups, respectively. A Spearman’s Rho test was used to assess correlation between preoperative and postoperative PTH levels.

A multiple binomial logistic regression was ultimately carried out to elaborate a predictive model of TPH, based on preoperative variables, progressively removing non-statistically significant variables in an iterative fashion.

Data were analyzed on SPSS Version 25.0 (IBM Corporation. Armonk, NY. US). Statistic tests were two-sided, where available, and a p value ≤ 0.05 was considered statistically significant.

The data that support the findings of this study are available from S. Paolo Hospital’s database. Restrictions apply to the availability of these data, which were used under license for this study.

Results

Indications to total thyroidectomy, long-term complications and data retrieval

Clinical indications for total thyroidectomy included: goiter with normal thyroid function (52), hyperfunctional goiter (29), Graves’s disease (12), oncologically confirmed or suspicious thyroid nodules (88). Surgery was provided by the same first operator at the same Service of Thyroid and Parathyroid Surgery in the Unit of Otolaryngology. Histological results were: simple hyperplasia (12), nodular hyperplasia (81), Differentiated Thyroid Carcinoma DTC (86), papillary and medullary carcinoma (1) and hyalinizing trabecular tumor (1).

Sixty-four patients (35.36%) showed transient postoperative hypocalcemia.

Data recovered about gender; age at surgery; preoperative PTH, TSH, serum calcium, serum creatinine and 25(OH)D levels; EGFR; postoperative PTH levels; and transient hypocalcemia are reported in Table 1.

Spearman’s Rho test showed a strongly significant correlation coefficient between preoperative and postoperative PTH (p = 0.001).

Comparing patients with and without transient postoperative hypocalcemia

Patients with and without TPH were compared in terms of sex, age at surgery, preoperative PTH, preoperative TSH, preoperative calcium, preoperative serum creatinine, EGFR, preoperative 25(OH)D level, and postoperative PTH, and postoperative calcium with a either a Mann–Whitney U test (for nonparametric data) or a Pearson’s chi square (for binomial data). There were no significant differences between the two groups in terms of age (p = 0.940), preoperative TSH (p = 0.708), preoperative calcium (p = 0.37), preoperative serum creatinine (p = 0.937), EGFR (p = 0.696), and sex distribution (p = 0.361).

There was a statistically significant difference in preoperative PTH (p = 0.038), postoperative PTH (p < 0.001) and vitamin D levels (p = 0.045). Patients with TPH had lower levels of postoperative PTH and had a higher proportion of either completely normal or deficient vitamin D levels than patients without TPH.

Table 1 Patient data according to postoperative transient hypocalcemia

| Parameter                      | General population (n = 181) | Postoperative eucalcemia group (n = 117) | Transient hypocalcemia group (n = 64) | Statistical significance |
|--------------------------------|-----------------------------|-----------------------------------------|--------------------------------------|-------------------------|
| Male to female ratio           | 50:131                      | 34:83                                   | 16:48                                | p = 0.361*              |
| Age at surgery                 | 54 ± 24.5 (17–84)           | 53 ± 24 (20–84)                         | 53 ± 23 (17–81)                      | p = 0.940**             |
| Preoperative PTH               | 62.60 ± 35.05 (18.6–237.6)  | 59.30 ± 26.20 (18.6–237.6)              | 68.80 ± 42.23 (25.90–183.50)         | p = 0.038**             |
| Preoperative TSH               | 1.69 ± 2.02 (0.015–23.5)    | 1.7 ± 1.98 (0.015–23.5)                 | 1.61 ± 1.9 (0.015–16.40)             | p = 0.708**             |
| Preoperative calcium           | 9.4 ± 0.4 (8.4–10.5)        | 9.5 ± 0.4 (8.6–10.5)                    | 9.4 ± 0.38 (8.4–10.3)                | p = 0.370**             |
| Preoperative creatinine        | 0.8 ± 0.2 (0.4–1.9)         | 0.8 ± 0.3 (0.4–1.9)                     | 0.7 ± 0.2 (0.6–1.6)                  | p = 0.937**             |
| EGFR                           | 87.53 ± 25.13 (33.67–159.21)| 87.53 ± 25.94 (33.67–159.21)           | 87.47 ± 21.42 (6.39–149.99)          | p = 0.696**             |
| Preoperative 25(OH) VitaminD (ng/ml) |                 |                                         |                                       |                         |
| < 10                           | 45 (24.86%)                 | 27 (23.08%)                             | 18 (28.12%)                          | p = 0.045**             |
| 10–30                          | 106 (58.56%)                | 76 (64.95%)                             | 30 (46.88%)                          |                         |
| > 30                           | 30 (16.58%)                 | 14 (11.97%)                             | 16 (25%)                             |                         |
| Postoperative PTH              | 33.8 ± 30.55 (3.4–180.9)    | 42.40 ± 25.10 (7.7–180.9)              | 15 ± 22.18 (3.4–95.8)                | p < 0.001**             |
| Postoperative calcium          | 8.1 ± 0.7 (6.4–9.5)         | 8.4 ± 0.2 (8.4–9.5)                     | 7.6 ± 0.5 (6.4–8.3)                  | p < 0.001**             |

The table reports variables for the general study population, further broken down into the postoperative transient hypocalcemia group and for the postoperative eucalcemia group. The p value for each statistical comparison between the two groups is reported (**Pearson’s Chi square; *Mann–Whitney U test). Values are reported as ratio (N%), absolute number (N(%)) or median ± interquartile range (minimum–maximum value). EGFR estimated glomerular filtration rate.
Comparing patients according to 25(OH)VitaminD levels

Patients from the three 25(OH)D level groups (deficiency, insufficient and normal) were compared in terms of all other evaluated variables with a either a Kuskal-Wallis test (for nonparametric data) or a Pearson’s chi square (for binomial data).

There was no difference in the three groups in terms of sex distribution ($p = 0.491$), age ($p = 0.604$), preoperative TSH ($p = 0.676$) and preoperative calcium level ($p = 0.455$). A statistically significant difference emerged in terms of preoperative PTH ($p = 0.038$), serum creatinine ($p = 0.013$), EGFR ($p = 0.023$), postoperative PTH ($p = 0.029$) and TPH rate ($p = 0.045$).

As reported in Table 2 the TPH rate difference between the three groups is remarkable (see also Fig. 1). Only 28.3% of patients with 25(OH)D insufficiency show TPH, significantly less than the other two groups (respectively 57.87% of patients with 25(OH)D deficiency and 53.33% of patients with normal levels of 25(OH)D).

Binomial regression

We elaborated a predictive model of TPH risk with a binomial regression, aimed at preoperative variables and patients’ characteristics. We iteratively removed from the regression all parameters with statistically non-significant $p$ values (sex, $p = 0.238$; age, $p = 0.418$; preoperative TSH, $p = 0.425$; preoperative calcium, $p = 0.471$; and EGFR, $p = 0.798$), building a regression model including only preoperative PTH ($p = 0.029$, odd ratio 1.012) and vitamin D level ($p = 0.029$, odd ratio 0.703 for vitamin D insufficiency).

The model showed good fit results (Hosmer and Lemeshow Test, chi square = 9.598; $p = 0.294$) and was able to correctly classify 64.4% of cases.

Discussion

To the authors’ knowledge, this is the first literature report describing this complex, non-linear relationship between 25(OH)D levels and risk of TPH.

Our 35.36% TPH rate is consistent with the literature and corresponds to a significant patient group given the sheer number of TT performed on a daily basis worldwide [4, 5].

By excluding patients with incidental parathyroidectomy (whose literature rate ranges from 5 to 20%) we were able to focus our case series on other determinants for TPH, most eminently 25(OH)D levels [19].

### Table 2 Patients data according to preoperative vitamin D levels

| Parameter                  | General population (n = 181) | Vitamin D deficiency (n = 45) | Vitamin D insufficiency (n = 106) | Normal vitamin D (n = 30) | Statistical significance |
|----------------------------|-------------------------------|-----------------------------|----------------------------------|--------------------------|--------------------------|
| Male to female ratio       | 50:131                        | 11:34                       | 28:78                            | 11:19                    | $p = 0.491^*$             |
| Age at surgery             | 54 ± 24.5 (17–84)             | 50 ± 26 (20–82)             | 55 ± 23 (20–81)                  | 57 ± 19.25 (17–84)       | $p = 0.604^{**}$          |
| Preoperative PTH           | 62.60 ± 35.05 (18.6–237.6)    | 79.60 ± 50.01 (24.8–237.6)  | 65.5 ± 31.225 (26.3–140.7)       | 51.75 ± 29.85 (18.6–129.2)| $p = 0.019^{**}$          |
| Preoperative TSH           | 1.69 ± 2.02 (0.015–23.5)      | 1.49 ± 1.45 (0.015–8.16)    | 1.64 ± 2.31 (0.015–23.5)         | 1.62 ± 1.9425 (0.27–16.4)| $p = 0.676^{**}$          |
| Preoperative calcium        | 9.4 ± 0.4 (8.4–10.5)          | 9.4 ± 0.3 (8.5–10.5)        | 9.5 ± 0.4 (8.6–10.4)             | 9.4 ± 0.35 (8.4–10.1)    | $p = 0.455^{**}$          |
| Preoperative creatinine     | 0.8 ± 0.2 (0.4–1.9)           | 0.7 ± 0.2 (0.4–1.6)         | 0.8 ± 0.275 (0.5–1.9)            | 0.88 ± 0.3 (0.6–1.5)     | $p = 0.013^{**}$          |
| EGFR                       | 87.53 ± 25.13 (33.67–159.21)  | 92.22 ± 22.03 (44.16–159.21)| 87.47 ± 25.635 (42.12–134.8)     | 82.96 ± 16.345 (33.67–143.2)| $p = 0.023^{**}$          |
| Postoperative PTH          | 33.8 ± 30.55 (3.4–180.9)      | 40.8 ± 35.9 (3.4–120.6)     | 35.4 ± 27.05 (3.4–180.9)         | 27.70 ± 18.325 (3.4–85.4)| $p = 0.029^{**}$          |
| Postoperative calcium       | 8.1 ± 0.7 (6.4–9.5)           | 8.4 ± 0.7 (6.4–9.1)         | 8.4 ± 0.55 (6.7–9.3)             | 8.2 ± 0.725 (6.4–9.5)    | $p = 0.545^{**}$          |
| Transient hypocalcemia     | No 117 (64.64%)               | 19 (42.22%)                 | 76 (71.7%)                       | 14 (46.67%)              | $p = 0.045^*$             |
|                           | Yes 64 (35.36%)               | 26 (57.78%)                 | 30 (28.3%)                       | 16 (53.33%)              |                          |

The table reports all patients’ variables in the general study population and subdivided according to the preoperative 25-hydroxyvitamin D levels. The $p$ value for each statistical comparison between the two groups is reported (*Pearson’s Chi square; **Kruskal Wallis test). Values are reported as ratio (N/N), absolute number (N(%)) or median ± interquartile range (minimum–maximum value). EGFR estimated glomerular filtration rate.
By comparing patients with and without TPH in our case series, several significant differences emerged. Patients with TPH are more frequently characterized by either deficitary or normal 25(OH)D levels and lower postoperative PTH (Table 1).

Postoperative hypoparathyroidism is an already known determinant of TPH. Nevertheless 71.9% of TPH patients in our series did not show postoperative hypoparathyroidism. Therefore, we chose to further explore the other significant variable, i.e., 25(OH)D level.

Instead of exploring a linear relationship between TPH and 25(OH)D value, as already proposed by other authors with inconclusive results, we classified patients in three standard groups according to their 25(OH)D level, defined as deficiency (< 10 ng/ml), insufficiency (11–30 ng/ml) and normality (> 30 ng/ml) [9–12, 18]. This grouped analysis revealed an unprecedentedly known correlation between TPH risk and 25(OH)D levels. Analyzing variables in the three groups, significant differences emerged not only for 25(OH)D levels, but also for pre- and postoperative PTH, serum creatinine, EGFR and TPH rate (see Table 2). The different TPH risk between groups might be justified by the metabolic differences emerged between patients, with hypothetical mechanisms that we are exploring in the following paragraphs.

### 25(OH)D deficiency group

This group is characterized by higher pre- and postoperative PTH, lower serum creatinine and higher EGFR. This group has the highest rate of TPH (57.87%). Our hypothesis is that insufficient 25(OH)D levels might reduce dietary calcium absorption and determine a mild secondary hyperparathyroidism state.

The pathogenesis of secondary hyperparathyroidism is complex and can involve both hypocalcaemia and vitamin D deficiency and insufficiency. 25-hydroxyvitamin D is converted into the active form of vitamin D [1,25-dihydroxyvitamin (1,25D)] by the cytochrome P450 enzyme, 1-alpha-hydroxylase (CYP27B1) in the kidney and other tissues. Hence, low serum 25D concentrations contribute to reduced 1,25D levels by providing less substrate for conversion. 1,25D reduces plasma PTH levels through its interactions with the vitamin D receptor in the parathyroid glands, and concomitantly increases the intestinal absorption of calcium. Consequently, decreased serum 1,25D levels lead to reductions in serum calcium and excessive PTH secretion.

Several studies demonstrate a strong negative correlation between 25-hydroxyvitamin D and PTH, which appears clear not only in a severe state of 25-hydroxyvitamin D deficiency with probable secondary hyperparathyroidism, but also in a

---

**Fig. 1** Column chart reporting the rate of patients with and without transient postoperative hypocalcemia according to their preoperative 25-hydroxyvitamin D levels
25-hydroxyvitamin D insufficiency, where PTH serum levels gradually increase [20]. Sayed-Hassan et al. investigated the relationships between 25OHD, PTH, and bone mineral density in 156 participants. The group confirmed the negative correlation between 25-hydroxyvitamin D and PTH: more than third (35.3%) of the case series had secondary hyperparathyroidism, with significant higher prevalence among participants in the lowest 25-hydroxyvitamin D quartile compared to those in the highest quartile [21].

PTH increase compensates 25(OH)D deficiency inducing bone resorption and calcium release. Following postoperative PTH reduction (though without significant rates of overt postoperative hypoparathyroidism), these patients' skeletal system is immediately allowed to retain more calcium. Indeed, 19 out of 45 patients in this group showed postoperative hypocalcemia, with a hungry bone disease-like mechanism. They might thus mimic the already known hungry bone disease that characterizes patients surgically treated for primary hyperparathyroidism [22, 23].

**25(OH)D insufficiency group**

This group shows intermediate preoperative PTH, serum creatinine and EGFR levels and the lowest TPH rate (28.3%). Though free from the tendency to secondary hyperparathyroidism characterizing patients with 25(OH)D deficiency, these patients show a moderate parathyroid hyperfunction. Our hypothesis is that these patients' calcium homeostasis is in a steady state, prone to continuous compensation. When PTH levels decrease after TT, serum calcium stability is provided by an appropriated bone mineralization and a flexible slight hyperfunction of parathyroid glands.

**Normal 25(OH)2 group**

The smallest group in our series is characterized by the lowest levels of pre- and postoperative PTH, lowest EGFR and highest serum creatinine. These patients show a significant prevalence of TPH (53.33%), only slightly lower than in patients with deficitary 25(OH)D. We hypothesize in these patients a less adaptive calcium homeostasis. In this patient group, the postoperative decrease of PTH due to thyroid neck compartment manipulation might not be buffered as quickly as in patients with insufficient 25(OH)D, thus facilitating TPH.

The identification of these three different metabolic groups might explain the conflicting literature reports about the role of 25(OH)D in TPH [9–12]. The TPH rate appears highest at the end of the 25(OH)D values spectrum. Such distribution might have hampered correlations on less conspicuous case series. Our observations are reinforced by the strong correlation emerging between pre- and postoperative PTH levels. The well-known postsurgical PTH drop is the least capable of explaining TPH in patients with higher preoperative levels of PTH. This observation calls for further metabolic motivations for TPH, which might be found in the previously expressed hypothesis.

Our binomial regression on the TPH risk further reinforces our observations. In this solid—though preliminary—predictive model, PTH levels and 25(OH)D levels allow identifying patients at risk for TPH. On the other hand, the regression suggests that serum creatinine and EGFR do not have a significant role in TPH risk. The different distribution of these values in the 3 25(OH)D groups might nevertheless have a role in other metabolic processes which are still open to exploration.

It has to be noted that our study has a major design limitation: the retrospective design. It limits the value of the study, despite our effort in minimizing biases and confounding factors and selecting a significant continuous patient series. Our observations would be undoubtedly strengthened by a prospective clinical trial, taking into account the same preoperative parameters and, possibly, providing preoperative therapy for patients at higher risk.

Our data indeed strengthen the need for a prospective clinical trial, investigating targeted preoperative 25(OH)D and/or calcium supplementation in the specific group of patients with 25(OH)D deficiency. Such supplementation might mitigate the hypothesized secondary hyperparathyroidism, reducing the TPH risk.

Our primary hypothesis is that the routine supplementation of calcium and/or 25(OH)D already scrutinized by other authors could become more effective if targeted, according to 25(OH)D and PTH status [24]. On the base of the result of our study of a greater risk of TPH in pre-operative deficiency and normal 25(OH)D groups than in insufficiency, only patients with pre-operative 25(OH)D deficiency and high PTH levels might benefit from mild preoperative 25(OH)D supplementation, in order to bring 25(OH)D from a deficiency to insufficiency, but not normal level. Pre-operative normal 25(OH)D/low PTH patients might require only calcium supplementation. Grzegory et al. reviewed 15 studies about preoperative calcium and 25(OH)D supplementation in patients undergoing TT [13]. Supplementation effectiveness was compared to no prophylaxis in 10 studies. The review showed a clinical and economic advantage for routine perioperative prophylactic supplementation of 25(OH)D and/or calcium as compared to no prophylaxis. Two of the reviewed studies were placebo-controlled and showed a significant reduction of TPH incidence in patients who received a preoperative supplementation of Calcium Carbonate or 25(OH)D [25, 26]. Given these literature data and our novel findings, it is our strong conviction that further studies in these regards will allow a better selection of patients at risk of TPH and optimize the cost-effectiveness of preoperative supplementation.
Conclusions

Our study revealed a correlation between transient postoperative hypocalcemia and 25-hydroxyvitaminD levels, hypothetically related to the mechanisms of calcium metabolism. Our work points towards the possibility to stratify the risk of transient postoperative hypocalcemia according to patients’ preoperative 25-hydroxyvitaminD status and suggests the need for further research towards targeted 25-hydroxyvitaminD and calcium supplementation.

Acknowledgements No other individual or organization have made contributions to the research of the manuscript.

Author contributions All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by AS, CR and LDP. The first draft of the manuscript was written by AS and CR and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Funding Open access funding provided by Università degli Studi di Milano within the CRUI-CARE Agreement. This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Availability of data and material The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

Declarations

Conflict of interest Financial interests: The authors declare they have no financial interests. Non-financial interests: none.

Code availability Not applicable.

Ethics approval Appropriate San Paolo Hospital’s institutional review board approval for all human investigations was obtained.

Consent to participate Informed consent was obtained from the participants.

Consent for publication Consent for publication was obtained from the participants.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Burge MR, Zeise TM, Johnsen MW, Conway MJ, Qualls CR (1998) Risks of complication following thyroidecomy. J Gen Intern Med 13(1):24–31
2. Wiseman JE, Mossanen M, Iuarte PHG, Bath JMT, Yeh MW (2010) An Algorithm informed by the parathyroid hormone level reduces hypocalcemic complications of thyroidecomy. World J Surg 34(3):532–537
3. Ravikumar K, Sadacharan D, Muthukumar S, Sundarram T, Periyasamy S, Suresh RV (2017) A prospective study on role of supplemental oral calcium and Vitamin D in prevention of postthyroidecomy hypocalcemia. Indian J Endocrinol Metab 21(4):498–503
4. Edefe O, Antakia R, Laskar N, Uttley L, Balasubramanian SP (2014) Systematic review and meta-analysis of predictors of post-thyroidecomy hypocalcemia. Br J Surg 101(4):307–320
5. Thomusch O et al (2000) Multivariate analysis of risk factors for postoperative complications in benign goiter surgery: prospective multicenter study in Germany. World J Surg 24(11):1335–1341
6. Chow T-L, Choi C-Y, Chiu AN-K (2014) Postoperative PTH monitoring of hypocalcemia expedites discharge after thyroidecomy. Am J Otolaryngol 35(6):736–740
7. White MG et al (2016) One-hour PTH after thyroidecomy predicts symptomatic hypocalcemia. J Surg Res 201(2):473
8. Orloff LA et al (2018) American thyroid association statement on postoperative hypoparathyroidism: diagnosis, prevention, and management in adults. Thyroid 28(7):830–841
9. Alkhaliili E, Ehrhart MD, Ayoubieh H, Burge MR (2017) does pre-operative Vitamin D deficiency predict postoperative hypocalcemia after thyroidecomy? Endocr Pract 23(1):5–9
10. Lee GH, Ku YH, Il Kim H, Lee M-C, Kim MJ (2015) Vitamin D level is not a predictor of hypocalcemia after total thyroidecomy. Langenbeck’s Arch. Surg. 400(5):617–622
11. Falcone TE et al (2015) Correlating pre-operative vitamin D status with post-thyroidecomy hypocalcemia. Endocr Pract 21(4):348–354
12. Danan D, Shonka DC (2017) Preoperative vitamin D level as predictor of post-thyroidecomy hypocalcemia in patients sustaining transient parathyroid injury. Head Neck 39(7):1378–1381
13. Grzegory and L. Pomorski (2018) Perioperative calcium and vitamin D supplementation in patients undergoing thyroidecomy—literature review. Pol Przegl Chir 90(4):46–50
14. Cannizzaro MA, Okatyeva V, Lo Bianco S, Caruso V, Buffone A (2018) Hypocalcemia after thyroidecomy: iPTH levels and iPTH decline are predictive? Retrospective cohort study. Ann Med Surg 30:42–45
15. Zhang S (2016) The application value of parathyroid hormone level in predicting post-operative hypocalcemia after total thyroidecomy. J Clin Otorhinolaryngol Head Neck Surg 30(1):39–41
16. Wang Y-H et al (2017) Risk factors for hypocalcemia and hypoparathyroidism following thyroidecomy: a retrospective Chinese population study. Cancer Manag Res 9:627–635
17. Levey AS, Coresh J, Greene T et al (2006) Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145(4):24754
18. Gupta S, Mahajan V, Yadav R et al (2018) Evaluation of serum Vitamin D levels in patients with systemic sclerosis and healthy controls: Results of a pilot study. Indian Dermatol Online J 9(4):250
19. Promberger R, Ott J, Kober F, Karik M, Freissmuth M, Hermann M (2011) Normal parathyroid hormone levels do not exclude
permanent hypoparathyroidism after thyroidectomy. Thyroid 21(2):145–150
20. Zhang Q, Shi L, Peng N, Xu S, Zhang M, Zhang S, Li H, Zhuang H, Gong M, Wu D, Wang R (2016) Serum concentrations of 25-hydroxyvitamin D and its association with bone mineral density and serum parathyroid hormone levels during winter in urban males from Guiyang. Southwest China Br J Nutr 115(6):960–966. https://doi.org/10.1017/S0007114515005383
21. Sayed-Hassan R, Abazid N, Koudsi A, Alourfi Z (2016) Vitamin D status and parathyroid hormone levels in relation to bone mineral density in apparently healthy Syrian adults. Arch Osteoporos 11:18. https://doi.org/10.1007/s11657-015-0245-0
22. Díez JJ, Anda E, Sastre J et al (2019) Prevalence and risk factors for hypoparathyroidism following total thyroidectomy in Spain: a multicentric and nation-wide retrospective analysis. Endocrine 66(2):405–415. https://doi.org/10.1007/s12020-019-02014-8 (Epub 2019 Jul 17. Erratum in: Endocrine. 2019 Oct 22;: PMID: 31317524)
23. Jain N, Reilly RF (2017) Hungry bone syndrome. Curr Opin Nephrol Hypertens 26(4):250–255
24. De Pasquale L, Sartori PV, Vicentini L et al (2015) Necessity of therapy for post-thyroidectomy hypocalcaemia: a multi-centre experience. Langenbecks Arch Surg 400(3):319–324. https://doi.org/10.1007/s00423-015-1292-0 (Epub 2015 Mar 8)
25. Oltmann SC, Brekke AV, Schneider DF et al (2015) Preventing postoperative hypocalcemia in patients with Graves disease: a prospective study. Ann Surg Oncol 22(3):952–958
26. Testa et al (2006) Calcitriol plus hydrochlorothiazide prevents transient post-thyroidectomy hypocalcemia. Horm Metab Res 38(12):821–826

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.